Some of the content on this page has been created using generative AI.
What is it about?
This article presents a Cochrane Review of two comparisons, Prostate Artery Embolization (PAE) versus Transurethral Resection of the Prostate (TURP) and PAE versus a sham procedure. The evidence suggests that PAE may result in similar improvements in urological symptom scores and quality of life (QoL) as TURP in the short-term, but the certainty of the evidence is low. PAE likely increases re-treatment rates and may reduce ejaculatory disorders. In the long-term, the effects on urological symptom scores and QoL were similar between the two procedures, but the certainty of the evidence is low. Compared to sham, PAE likely improves urological symptom scores and QoL, but no major adverse events or re-treatment were reported in either study group. The review also notes that guideline recommendations based on this evidence base are currently contradictory and potentially in flux.
Featured Image
Why is it important?
This research is important because it provides valuable insights into the effectiveness and safety of prostate artery embolization (PAE) compared to transurethral resection of the prostate (TURP) and a sham procedure in treating lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). The findings of this study can help guide clinical practice and inform the development of guidelines and recommendations for the treatment of BPH. Key Takeaways: 1. PAE may result in a somewhat lesser but overall similar improvement in urological symptom score and quality of life (QoL) compared to TURP in the short-term (up to 12 months of follow-up). However, the risk of re-treatment is higher with PAE. 2. PAE is likely to increase re-treatment rates compared to a sham procedure. 3. PAE may reduce ejaculatory disorders compared to TURP and a sham procedure. 4. In the long-term (>12 months of follow-up), PAE may result in similar improvement in urological symptom score and QoL compared to TURP. However, the risk of re-treatment is higher with PAE. 5. There is no difference in erectile function between PAE and TURP, but PAE may reduce ejaculatory disorders. 6. The current AUA guideline recommends against the use of PAE outside of clinical trials, while the National Institute for Health and Care Excellence indicates that PAE is a treatment option for LUTS caused by BPH. 7. The review has limitations, including the possibility of missed unpublished studies and the small number of studies included, which may have contributed to the risk of publication bias.
AI notice
Read the Original
This page is a summary of: Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review, BJU International, July 2022, Wiley,
DOI: 10.1111/bju.15823.
You can read the full text:
Contributors
Be the first to contribute to this page







